



## Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

January 3, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 3, 2022-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.

The webcast of the presentation may be accessed in the [Investors](#) section of the Company's website at [www.concertpharma.com](http://www.concertpharma.com). A replay of the conference webcast will be available on Concert's website for two weeks following the presentation.

### About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its [DCF Platform](#)<sup>®</sup> (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead [product candidate](#) is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit [www.concertpharma.com](http://www.concertpharma.com) or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220102005016/en/): <https://www.businesswire.com/news/home/20220102005016/en/>

Justine Koenigsberg  
(781) 674-5284  
[ir@concertpharma.com](mailto:ir@concertpharma.com)

Source: Concert Pharmaceuticals, Inc.